Besides that, pretreatment with the peptide dramatically enhanced the effects of cisplatin treatment at non-toxic concentration, such as reduction of Mcl-1 and Bcl-2 levels as well as the elevation of p53 and Bax in cisplatin-treated lung cancer cells (Fig. 5a). Here, BAX is linked to lung carcinoma.